Avacta Group Plc (AVCT) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen. Welcome to the Evactor Group PLC Interim Results Investor presentation. Throughout today's recording meeting, attendees will be in listen-only mode. Questions are encouraged. They can be submitted at any time just using the Q&A tab situated on the right-hand corner of your screen. Please simply type in your questions at any time and press send. Due to the significant attendance on today's call, the company will not be in a position to answer every question received in the meeting itself. However, the company can review all questions submitted today and will publish those responses where it's appropriate to do so. Before we begin, we'd like to submit the following poll, and I'm sure the company will be most grateful for your participation. I'd now like to hand over to the management team. Chris, Brian, good afternoon. Good afternoon, Mark. Thank you for having us and a good morning to our colleagues. across the pond in the States. My name is Christina Coughlin. I am the CEO of Avacta Therapeutics coming to you here from White City, London at our headquarters. And I am joined by my Chief Financial Officer, Brian Hahn. We look forward to delivering to you today our interim results for the period ending June 30th, 2025. As part of our presentation, both Brian and I will be making forward-looking statements. Recent research and development highlights from the company. We are currently enrolling our clinical stage program, Faridoxorubicin, happy to bring that name to you for the first time today. It has been issued by the World Health Organization, FAPDOCS or ABA 6000. We continue to enroll in the expansion cohorts in this program. Our second clinical program, and I use that term as FAP Exotecan, is quickly approaching the clinic. FAP ...